Scopus Biopharma Inc   (SCPS)
Other Ticker:  
Price: $0.0002 $0.00 0.000%
Day's High: $0.0002 Week Perf: 100 %
Day's Low: $ 0.00 30 Day Perf: -66.67 %
Volume (M): 0 52 Wk High: $ 0.07
Volume (M$): $ 0 52 Wk Avg: $0.03
Open: $0.00 52 Wk Low: $0.00

 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 40
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -9
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Scopus Biopharma Inc
Scopus Biopharma Inc is a pharmaceutical company that specializes in developing and commercializing innovative therapies for various diseases. The company focuses on the research and development of biopharmaceutical products, with an emphasis on drugs that target autoimmune diseases and cancer. Their aim is to address unmet medical needs and provide patients with more effective treatment options. Scopus Biopharma Inc leverages advanced technologies and scientific expertise to deliver novel therapies to the market and improve patient outcomes.

   Company Address: 420 Lexington Avenue, Suite 300 New York 10170 NY
   Company Phone Number: 479-2513   Stock Exchange / Ticker: SCPS


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Scopus Biopharma Inc

Scopus Biopharma Inc. Shows Promising Improvement in Financials, Reducing Operating Deficit in Q2 2023

Understanding the Shareholders' Perspective on SCPS Earnings Season
The recent earnings season of April to June 30, 2023, at SCPS, has left shareholders pondering over various aspects of the company's performance. While the shareholders have not assumed any major moderation at the business during this period, they have taken notice of the company's operating deficit, which stood at $-2.928858 million. However, these numbers compare favorably to the results of the second quarter of 2022, where the operating deficit was $-3.319603 million.
One of the significant signals for the course of SCPS is its ability to reduce the operating deficit. This marks a positive trend in the company's financial picture. As ascending companies like Scopus Biopharma Inc. continue to unveil their respective revenue sources, it becomes crucial for them to operate efficiently and aim for the next growth phase.

Scopus Biopharma Inc

Scopus Biopharma Inc Faces Operating Deficit in Q1 2023 ? What's Next for the Healthcare Powerhouse?

Scopus Biopharma Inc is a major pharmaceutical preparations company operating in the healthcare industry. The company is dedicated to the discovery and development of innovative therapies for the treatment of serious medical conditions. Scopus Biopharma Inc has a strong presence in the market and is known for its expertise in the field of biotechnology.
Over the years, Scopus Biopharma Inc has gained a reputation for its commitment to research and development and has made significant contributions to the healthcare industry. The company has a robust pipeline of products that are in various stages of development, and it has also collaborated with several leading healthcare companies to bring innovative therapies to the market.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com